Innoviva Net Profit Margin 2010-2024 | INVA
Innoviva net profit margin from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
| Innoviva Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2024-06-30 |
$0.33B |
$0.15B |
44.24% |
| 2024-03-31 |
$0.31B |
$0.18B |
58.52% |
| 2023-12-31 |
$0.31B |
$0.18B |
58.06% |
| 2023-09-30 |
$0.29B |
$0.05B |
17.24% |
| 2023-06-30 |
$0.29B |
$0.23B |
80.69% |
| 2023-03-31 |
$0.32B |
$0.23B |
73.82% |
| 2022-12-31 |
$0.33B |
$0.22B |
64.95% |
| 2022-09-30 |
$0.37B |
$0.29B |
78.55% |
| 2022-06-30 |
$0.40B |
$0.10B |
24.50% |
| 2022-03-31 |
$0.40B |
$0.19B |
47.10% |
| 2021-12-31 |
$0.39B |
$0.27B |
67.43% |
| 2021-09-30 |
$0.38B |
$0.31B |
82.40% |
| 2021-06-30 |
$0.37B |
$0.27B |
72.40% |
| 2021-03-31 |
$0.34B |
$0.25B |
73.55% |
| 2020-12-31 |
$0.34B |
$0.22B |
66.47% |
| 2020-09-30 |
$0.32B |
$0.22B |
66.87% |
| 2020-06-30 |
$0.30B |
$0.23B |
76.00% |
| 2020-03-31 |
$0.29B |
$0.19B |
66.32% |
| 2019-12-31 |
$0.26B |
$0.16B |
60.54% |
| 2019-09-30 |
$0.27B |
$0.38B |
141.89% |
| 2019-06-30 |
$0.26B |
$0.38B |
146.74% |
| 2019-03-31 |
$0.26B |
$0.40B |
151.52% |
| 2018-12-31 |
$0.26B |
$0.40B |
151.72% |
| 2018-09-30 |
$0.25B |
$0.19B |
75.70% |
| 2018-06-30 |
$0.24B |
$0.17B |
70.17% |
| 2018-03-31 |
$0.23B |
$0.15B |
63.91% |
| 2017-12-31 |
$0.22B |
$0.13B |
61.47% |
| 2017-09-30 |
$0.19B |
$0.10B |
52.60% |
| 2017-06-30 |
$0.18B |
$0.09B |
52.27% |
| 2017-03-31 |
$0.15B |
$0.07B |
48.32% |
| 2016-12-31 |
$0.13B |
$0.06B |
44.36% |
| 2016-09-30 |
$0.11B |
$0.04B |
33.93% |
| 2016-06-30 |
$0.09B |
$0.02B |
19.35% |
| 2016-03-31 |
$0.07B |
$-0.01B |
-6.94% |
| 2015-12-31 |
$0.06B |
$-0.02B |
-36.36% |
| 2015-09-30 |
$0.04B |
$-0.04B |
-102.56% |
| 2015-06-30 |
$0.03B |
$-0.06B |
-215.38% |
| 2015-03-31 |
$0.02B |
$-0.11B |
-700.00% |
| 2014-12-31 |
$0.01B |
$-0.17B |
-2112.50% |
| 2014-09-30 |
$0.00B |
$-0.20B |
-10150.00% |
| 2014-06-30 |
$0.00B |
$-0.23B |
-22900.00% |
| 2014-03-31 |
$0.00B |
$-0.20B |
-20100.00% |
| 2013-12-31 |
$0.00B |
$-0.17B |
-5666.67% |
| 2013-09-30 |
$0.01B |
$-0.15B |
-1887.50% |
| 2013-06-30 |
$0.01B |
$-0.14B |
-1544.44% |
| 2013-03-31 |
$0.01B |
$-0.14B |
-1555.56% |
| 2012-12-31 |
$0.14B |
$-0.02B |
-13.33% |
| 2012-09-30 |
$0.13B |
$-0.02B |
-17.91% |
| 2012-06-30 |
$0.14B |
$-0.02B |
-14.39% |
| 2012-03-31 |
$0.14B |
$-0.01B |
-5.56% |
| 2011-12-31 |
$0.02B |
$-0.12B |
-504.35% |
| 2011-09-30 |
$0.03B |
$-0.10B |
-392.00% |
| 2011-06-30 |
$0.02B |
$-0.09B |
-366.67% |
| 2011-03-31 |
$0.02B |
$-0.08B |
-350.00% |
| 2010-12-31 |
$0.02B |
$-0.08B |
-350.00% |
| 2010-09-30 |
$0.02B |
$-0.09B |
-414.29% |
| 2010-06-30 |
$0.02B |
$-0.09B |
-400.00% |
| 2010-03-31 |
$0.02B |
$-0.09B |
-423.81% |
| 2009-12-31 |
$0.03B |
$-0.09B |
-340.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.205B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
